Interim analysis [Study As­sess­ment]

posted by Ohlbe – France, 2014-10-15 01:53 (4273 d 04:53 ago) – Posting: # 13709
Views: 8,338

Dear Samaya,

❝ When data for first half subjects (N: 28) was analysed, we got following results.

❝ Cmax ratio: 87 (CI: 80.88-95.13)

❝ AUC ratio: 87 (CI: 81.85-94.18)


Did you plan for a two-stage design (which I understand is tricky for full replicate studies) ? If so, why proceed to the second stage though BE was demonstrated ? If not, then what was the reason for doing an interim analysis ? Was it planned in the protocol (with appropriate alpha-correction) ?

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
388 visitors (0 registered, 388 guests [including 20 identified bots]).
Forum time: 06:46 CEST (Europe/Vienna)

Don’t compromise yourself.
You are all you’ve got.    Janis Joplin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5